Remdesivir triphosphate triethylammonium – GS-443902 – CAS 2725956-16-9


Remdesivir triphosphate triethylammonium salt is synthesised by Santiago Lab (Prague, Czech Republic).

All products are lyophilized and can easily sustain the shipment oversee (shipping with DHL on dry ice to ensure that product arrives in a perfect state). We are also providing Remdesivir triphosphate in the form of Na+ salt.

Purity (LC-MS)

99%+ | Certificate of Analysis

Package contents

Remdesivir triphosphate triethylammonium salt

This compound is for research use only. We do not sell to patients.
1 mg

In stock

5 mg

In stock

10 mg

In stock

25 mg

In stock

50 mg

In stock

100 mg

In stock


In stock


In stock


Remdesivir triphosphate triethylammonium salt


CAS: 2725956-16-9

IUPAC Name: 2-C-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D-altrononitrile 6-triphosphate trisodium

Other names: GS-441524 triphosphate, Remdesivir metabolite, Remdesivir triphosphate metabolite, Remdesivir triphosphate triethylammonium salt

Molecular weight: 834.78 g/mol 

Molecular formula: C30H61N8O13P3

Storage: -20 °C, protect from light, stored under argon

All our products are lyophilized to ensure long shelf life and the best shipping conditions. We already have tens of satisfied clients across three continents.

We are also providing Remdesivir triphosphate in the form of Na+ salt.


Remdesivir triphosphate triethylammonium salt is synthesised by Santiago Lab (Prague, Czech Republic). GS-443902 is the active triphosphate metabolite of Remdesivir with activity against zoonotic feline infectious peritonitis virus (FIPV) and severe acute respiratory syndrome (SARS) virus from the Coronaviridae family. GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. 

Remdesivir, developed by Gilead Sciences, is an adenosine prodrug that metabolizes into its active form GS-441524, which interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production.

Chemicals are distributed worldwide

Buy Remdesivir triphosphate triethylammonium salt now, get your order in 48 hours
  • Shipping through DHL in 48 hours. We can also arrange shipping on dry ice.
  • All compounds are safely and rigorously packed
  • We are sending triphosphates every Monday
  • Delivery time 24 hours in Europe, 24-48 hours to USA, Canada, Asia
  • We are sending the invoice the same day as the shipment
  • We can modify the invoice for the academic institution so that the order can be paid from grants
  • Payment terms 30 days net

1. Shannon, A.; Le, N. T.-T.; Selisko, B.; Eydoux, C.; Alvarez, K.; Guillemot, J.-C.; Decroly, E.; Peersen, O.; Ferron, F.; Canard, B., Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020, 178, 104793.
2. Ju, J.; Li, X.; Kumar, S.; Jockusch, S.; Chien, M.; Tao, C.; Morozova, I.; Kalachikov, S.; Kirchdoerfer, R. N.; Russo, J. J., Nucleotide analogues as inhibitors of SARS-CoV polymerase. bioRxiv 2020, 1-18.
3. Jordan, P. C.; Liu, C.; Raynaud, P.; Lo, M. K.; Spiropoulou, C. F.; Symons, J. A.; Beigelman, L.; Deval, J., Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. PLoS Pathogens 2018, 14 (2), e1006889/1-e1006889/23.
4. Siegel, D.; Hui, H. C.; Doerffler, E.; Clarke, M. O.; Chun, K.; Zhang, L.; Neville, S.; Carra, E.; Lew, W.; Ross, B.; Wang, Q.; Wolfe, L.; Jordan, R.; Soloveva, V.; Knox, J.; Perry, J.; Perron, M.; Stray, K. M.; Barauskas, O.; Feng, J. Y.; Xu, Y.; Lee, G.; Rheingold, A. L.; Ray, A. S.; Bannister, R.; Strickley, R.; Swaminathan, S.; Lee, W. A.; Bavari, S.; Cihlar, T.; Lo, M. K.; Warren, T. K.; Mackman, R. L., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem. 2017, 60 (5), 1648-1661.
5. Clarke, M. O. N. H.; Jordan, R.; Mackman, R. L.; Ray, A. S.; Siegel, D. Preparation of amino acid-containing nucleosides for treating flaviviridae virus infections. 2017-US28243, 2017184668, 20170419., 2017.
6. Warren, T. K.; Jordan, R.; Lo, M. K.; Ray, A. S.; Mackman, R. L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H. C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G.; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B. P.; Grimes, E.; Welch, L. S.; Gomba, L.; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; Nagle, E. R.; Kugelman, J. R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M. O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K. M.; Trancheva, I.; Feng, J. Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M. R.; Flint, M.; McMullan, L. K.; Chen, S.-S.; Fearns, R.; Swaminathan, S.; Mayers, D. L.; Spiropoulou, C. F.; Lee, W. A.; Nichol, S. T.; Cihlar, T.; Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature (London, United Kingdom) 2016, 531 (7594), 381-385.
7. Chun, B. K.; Clarke, M. O. N. H.; Doerffler, E.; Hui, H. C.; Jordan, R.; Mackman, R. L.; Parrish, J. P.; Ray, A. S.; Siegel, D. Preparation of nucleosides and methods for treating Filoviridae virus infections. 2015-14926062 20160122374, 20151029., 2016.
8. Cho, A.; Saunders, O. L.; Butler, T.; Zhang, L.; Xu, J.; Vela, J. E.; Feng, J. Y.; Ray, A. S.; Kim, C. U., Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorganic & Medicinal Chemistry Letters 2012, 22 (8), 2705-2707.

Related products: